256 related articles for article (PubMed ID: 33626864)
1. Chronic organ injuries in children with sickle cell disease.
Allali S; Taylor M; Brice J; de Montalembert M
Haematologica; 2021 Jun; 106(6):1535-1544. PubMed ID: 33626864
[TBL] [Abstract][Full Text] [Related]
2. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
3. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease.
Pashankar FD; Carbonella J; Bazzy-Asaad A; Friedman A
Pediatrics; 2008 Apr; 121(4):777-82. PubMed ID: 18381543
[TBL] [Abstract][Full Text] [Related]
5. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis.
Khargekar N; Banerjee A; Athalye S; Mahajan N; Kargutkar N; Tapase P; Madkaikar M
Syst Rev; 2024 Feb; 13(1):60. PubMed ID: 38331925
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
8. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
Kassim AA; DeBaun MR
Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
[TBL] [Abstract][Full Text] [Related]
9. Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404).
Chevret S; Verlhac S; Ducros-Miralles E; Dalle JH; de Latour RP; de Montalembert M; Benkerrou M; Pondarré C; Thuret I; Guitton C; Lesprit E; Etienne-Julan M; Elana G; Vannier JP; Lutz P; Neven B; Galambrun C; Paillard C; Runel C; Jubert C; Arnaud C; Kamdem A; Brousse V; Missud F; Petras M; Doumdo-Divialle L; Berger C; Fréard F; Taieb O; Drain E; Elmaleh M; Vasile M; Khelif Y; Bernaudin M; Chadebech P; Pirenne F; Socié G; Bernaudin F
Contemp Clin Trials; 2017 Nov; 62():91-104. PubMed ID: 28821470
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
Suliman H; Wali Y; Al Saadoon M; Zechariah M; William RR; Gujjar A; Pathare A
J Pediatr Hematol Oncol; 2009 Jan; 31(1):42-4. PubMed ID: 19125086
[TBL] [Abstract][Full Text] [Related]
11. [Cerebral vasculopathy in pediatric sickle-cell anemia].
Kossorotoff M; Grevent D; de Montalembert M
Arch Pediatr; 2014 Apr; 21(4):404-14. PubMed ID: 24630541
[TBL] [Abstract][Full Text] [Related]
12. Big strokes in small persons.
Adams RJ
Arch Neurol; 2007 Nov; 64(11):1567-74. PubMed ID: 17998439
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Laurin LP; Nachman PH; Desai PC; Ataga KI; Derebail VK
Nephrol Dial Transplant; 2014 Jun; 29(6):1211-8. PubMed ID: 24084325
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Gladwin MT; Sachdev V; Jison ML; Shizukuda Y; Plehn JF; Minter K; Brown B; Coles WA; Nichols JS; Ernst I; Hunter LA; Blackwelder WC; Schechter AN; Rodgers GP; Castro O; Ognibene FP
N Engl J Med; 2004 Feb; 350(9):886-95. PubMed ID: 14985486
[TBL] [Abstract][Full Text] [Related]
15. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
Mack AK; Thompson AA
J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
17. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
19. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
20. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
